APA (7th ed.) Citation

Ilson, D., Moughan, J., Safran, H., Wigle, D., Depetrillo, T., Haddock, M., . . . Leonard, K. (2020). O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. Annals of Oncology, 31, 235. https://doi.org/10.1016/j.annonc.2020.04.063

Chicago Style (17th ed.) Citation

Ilson, D., et al. "O-10 Trastuzumab with Trimodality Treatment for Esophageal Adenocarcinoma with HER2 Overexpression: NRG Oncology/RTOG 1010." Annals of Oncology 31 (2020): 235. https://doi.org/10.1016/j.annonc.2020.04.063.

MLA (9th ed.) Citation

Ilson, D., et al. "O-10 Trastuzumab with Trimodality Treatment for Esophageal Adenocarcinoma with HER2 Overexpression: NRG Oncology/RTOG 1010." Annals of Oncology, vol. 31, 2020, p. 235, https://doi.org/10.1016/j.annonc.2020.04.063.